An orally administrable therapeutic protein is provided by combining the therapeutic protein with a stabilizing agent in an aqueous solution. The solution is coated onto nonpareils and microencapsulated with a water emulsifiable enteric coating composition. The microcapsules are orally administered. The coating protects the protein as it passes through the stomach. Upon reaching the small intestines, the basic pH of the intestinal juices will dissolve the coating, allowing the protein to be released and induce antigen specific immune response which has the specificity of the native molecule. The stabilizing agent protects the therapeutic protein from denaturation during the encapsulation process.

Uma proteína therapeutic oral administrable é fornecida combinando a proteína therapeutic com um agente estabilizando-se em uma solução aqueous. A solução é revestida em nonpareils e microencapsulated com uma composição revestindo enteric emulsifiable da água. Os microcapsules são administrados oral. O revestimento protege a proteína enquanto passa através do estômago. Em cima de alcançar os intestines pequenos, o pH básico dos sucos intestinal dissolverá o revestimento, permitindo que a proteína seja liberada e induzirá a resposta imune específica do antígeno que tem o specificity da molécula nativa. O agente estabilizando-se protege a proteína therapeutic do denaturation durante o processo do encapsulation.

 
Web www.patentalert.com

< Dry cocoa mix containing a mixture of non-alkalized and alkalized cocoa solids

< Use of CYP52A2A promoter to increase gene expression in yeast

> Process for treating oils containing antioxidant compounds

> Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders

~ 00083